S. Bihr

Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma1

H. Moch, N. Beerenwinkel, T. Hermanns, 2019, Neoplasia.

MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients

H. Moch, C. Karlo, P. Schraml, 2016, Oncotarget.

Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer

M. Maathuis, C. Britschgi, A. Curioni-Fontecedro, 2021, Cancers.

Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance

H. Moch, P. Schraml, U. Vogl, 2016, BMC Cancer.

MiR-99 b-5 p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients

H. Moch, C. Karlo, P. Schraml, 2016 .